UNC Hospitals preps for triple-tandem stem cell transplantNBC17.comA Carrboro man will get the first triple-tandem stem cell transplant done at UNC Hospitals to treat testicular cancer. (more) A Carrboro man is getting the first triple-tandem stem cell…
OncLiveNoteworthy Research Spans Range of MalignanciesOncLiveRituximab antibodies (turquoise) bind to the CD20 cell-surface markers on B-cells. A second paper reported the results of a most interesting phase III randomized trial that the Eastern Cooper…
BBC NewsMother honours Anthony Kelly's organ donation wishesBBC NewsA mother says she has honoured her son's wishes and donated his organs to other people following his death after a road collision in Denbighshire. Minibus passenger Anthony Kel…
Transplants Using Stem Cells From The Blood Or Bone Marrow Yield Similar …The MDS BeaconFor blood cancer patients receiving a stem cell transplant from an unrelated donor, survival rates appear to be similar regardless of whether the stem cells were …
Oral cyclosporine observed most effective in infection-driven atopic dermatitisPediatric SuperSiteTo determine how effective oral cyclosporine would be in children for the treatment of atopic dermatitis (AD) unresponsive to topical corticosteroids and …
Fresenius Medical Care AG & Co. KGaA; Analysis of Agreement Containing Consent …Insurance News Net (press release)Kidney transplantation is the only alternative to dialysis for ESRD patients. However, the wait-time for donor kidneys–during which…
IMARC Group Releases the Most Comprehensive Study on the US Follow-on …PharmiWeb.com (press release)… Interferon Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab (Herceptin), Rituximab (Mabthera/Rituxan), Cetuxima…
Rigel Announces Fourth Quarter and Year End 2011 Financial ResultsMarketWatch (press release)In the fourth quarter of 2011, Rigel initiated Phase 1 clinical studies of R548 with a focus on its potential to treat transplant rejection and other immune sy…
Heart failure drug gets initial go-aheadNursing TimesA drug that can reduce the need for heart failure patients to be hospitalised by 30% has been given the green light by European regulators. You now need to register for FREE to read our news. Please …
InPharmIndian CMO will make Roche blockbustersInPharmMeanwhile, a separate report in the Economic Times has suggested that the deal could also be extended to cover Roche's non-Hodgkin's lymphoma therapy MabThera/Rituxan (rituximab). The deal is…